Results 71 to 80 of about 10,061 (158)

Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients

Platelets, 2017
Three oral platelet P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are available for reducing the risk of cardiovascular death and stent thrombosis in patients with acute coronary syndromes (ACS).
Rebecca Gosling, Momina Yazdani, Yasir Parviz, Ian R Hall, Ever D. Grech, Julian P Gunn, Robert F. Storey, Javaid Iqbal   +7 more
doaj   +1 more source

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis

BMC Cardiovascular Disorders, 2018
Background Due to limitations associated with clopidogrel following percutaneous coronary intervention (PCI), other newer oral anti-platelet agents are being studied.
Pravesh Kumar Bundhun, Feng Huang
doaj   +1 more source

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel

Clinical Medicine Insights: Cardiology, 2016
Objectives A growing body of clinical and laboratory evidence indicates that inflammation plays a crucial role in atherosclerosis. In the present study, we compared the effects of clopidogrel and prasugrel on high-sensitivity C-reactive protein (hs-CRP ...
Shokoufeh Hajsadeghi, Mandana Chitsazan, Mitra Chitsazan, Negar Salehi, Ahmad Amin, Arash Amin Bidokhti, Nima Babaali, Armin Bordbar, Maral Hejrati, Samar Moghadami   +9 more
doaj   +1 more source

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Vascular Health and Risk Management, 2009
Nicholas B Norgard,1 Mazen Abu-Fadel21University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA; 2University of Oklahoma Health Sciences Center, Cardiovascular Section, Oklahoma City, OK, USAAbstract: Antiplatelet agents are
Nicholas B Norgard, Mazen Abu-Fadel
doaj  

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention

Open Heart, 2019
Background There is a paucity of real-world outcome data comparing clopidogrel, prasugrel and ticagrelor in primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
Jim McLenachan, Christopher Malkin, Daniel J Blackman, John Greenwood, Stephen Wheatcroft, Paul Baxter, Arvindra Krishnamurthy, Claire Keeble, Michelle Anderson, Kathryn Somers, Natalie Burton-Wood, Charlotte Harland, Jonathan Blaxill   +12 more
doaj   +1 more source

Impact of Society Guidelines on Trends in Use of Newer P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Over the past decade, major society guidelines have recommended the use of newer P2Y12 inhibitors over clopidogrel for those undergoing percutaneous coronary intervention for acute coronary syndrome.
Mohamed O. Mohamed, Evangelos Kontopantelis, Mirvat Alasnag, Leila Abid, Amitava Banerjee, Andrew S. P. Sharp, Christos Bourantas, Alex Sirker, Nick Curzen, Mamas A. Mamas   +9 more
doaj   +1 more source

Clopidogrel, ticagrelor, prasugrel or an alternation of two P2Y12 in patients with acute myocardial infarction with cardiogenic shock

Frontiers in Cardiovascular Medicine
BackgroundData are lacking on the effects of the alternation of P2Y12 receptor antagonists (P2Y12) on bleeding and outcome in patients with myocardial infarction (MI) with cardiogenic shock (CS). We compared the effects of different P2Y12 and alternation
Vojko Kanic, Gregor Kompara
doaj   +1 more source

Prasugrel [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Prasugrel in the Elderly [PDF]

Circulation, 2018
openaire   +2 more sources

In silico Investigation on Clopidogrel, Prasugrel and Ticagrelor as Potential Mono Antiplatelet Therapy for Acute Coronary Syndrome

MCBS (Molecular and Cellular Biomedical Sciences)
Background: In acute coronary syndrome (ACS), antiplatelet therapy is crucial for inhibiting platelet aggregation. Dual antiplatelet therapy (DAPT) commonly employs aspirin along with clopidogrel, prasugrel, or ticagrelor. This is well known that aspirin
Muhammad Naufal Hibatullah, Suryono Suryono, Sheilla Rachmania   +2 more
doaj   +1 more source